Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 Adherens junction 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
2 Adherens junction 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
3 Adherens junction 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
4 Adherens junction 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
5 Adherens junction 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
6 Adherens junction 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
7 Adherens junction 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
8 Bladder cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
9 Bladder cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
10 Bladder cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
11 Bladder cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
12 Bladder cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
13 Bladder cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
14 Bladder cancer 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
15 Breast cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
16 Breast cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
17 Breast cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
18 Breast cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
19 Breast cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
20 Breast cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
21 Breast cancer 💬
 [3] EGFR, ERBB2, FLT4 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
22 Calcium signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
23 Calcium signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
24 Calcium signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
25 Calcium signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
26 Calcium signaling pathway 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
27 Calcium signaling pathway 💬
 [3] EGFR, ERBB2, ERBB4 💬 Neratinib 💬 Neratinib [1] 34 💬
28 Calcium signaling pathway 💬
 [4] EGFR, ERBB2, FLT4, KDR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
29 Central carbon metabolism in cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
30 Central carbon metabolism in cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
31 Central carbon metabolism in cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
32 Central carbon metabolism in cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
33 Central carbon metabolism in cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
34 Central carbon metabolism in cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
35 Central carbon metabolism in cancer 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
36 Chemical carcinogenesis - reactive oxygen species 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
37 Chemical carcinogenesis - reactive oxygen species 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
38 Chemical carcinogenesis - reactive oxygen species 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
39 Chemical carcinogenesis - reactive oxygen species 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
40 Chemical carcinogenesis - reactive oxygen species 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
41 Chemical carcinogenesis - reactive oxygen species 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
42 Chemical carcinogenesis - reactive oxygen species 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
43 Chemical carcinogenesis - receptor activation 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
44 Chemical carcinogenesis - receptor activation 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
45 Chemical carcinogenesis - receptor activation 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
46 Chemical carcinogenesis - receptor activation 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
47 Chemical carcinogenesis - receptor activation 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
48 Chemical carcinogenesis - receptor activation 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
49 Chemical carcinogenesis - receptor activation 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
50 Choline metabolism in cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
51 Choline metabolism in cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
52 Choline metabolism in cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
53 Choline metabolism in cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
54 Choline metabolism in cancer 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
55 Choline metabolism in cancer 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
56 Choline metabolism in cancer 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
57 Colorectal cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
58 Colorectal cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
59 Colorectal cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
60 Colorectal cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
61 Colorectal cancer 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
62 Colorectal cancer 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
63 Colorectal cancer 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
64 Coronavirus disease - COVID-19 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
65 Coronavirus disease - COVID-19 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
66 Coronavirus disease - COVID-19 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
67 Coronavirus disease - COVID-19 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
68 Coronavirus disease - COVID-19 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
69 Coronavirus disease - COVID-19 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
70 Coronavirus disease - COVID-19 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
71 Cushing syndrome 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
72 Cushing syndrome 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
73 Cushing syndrome 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
74 Cushing syndrome 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
75 Cushing syndrome 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
76 Cushing syndrome 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
77 Cushing syndrome 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
78 EGFR tyrosine kinase inhibitor resistance 💬
 [3] AXL, KDR, MET 💬 Cabozantinib 💬 Cabozantinib [1] 34 💬
79 EGFR tyrosine kinase inhibitor resistance 💬
 [1] BCL2 💬 Venetoclax 💬 Venetoclax [1] 28 💬
80 EGFR tyrosine kinase inhibitor resistance 💬
 [1] BRAF 💬 Dabrafenib 💬 Dabrafenib [1] 34 💬
81 EGFR tyrosine kinase inhibitor resistance 💬
 [4] BRAF, KDR, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib [2] 34, 86 💬
82 EGFR tyrosine kinase inhibitor resistance 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
83 EGFR tyrosine kinase inhibitor resistance 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
84 EGFR tyrosine kinase inhibitor resistance 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
85 EGFR tyrosine kinase inhibitor resistance 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
86 EGFR tyrosine kinase inhibitor resistance 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
87 EGFR tyrosine kinase inhibitor resistance 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
88 EGFR tyrosine kinase inhibitor resistance 💬
 [3] EGFR, ERBB2, KDR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
89 EGFR tyrosine kinase inhibitor resistance 💬
 [1] FGFR2 💬 Palifermin 💬 Palifermin [5] 13, 36, 38, 39, 65 💬
90 EGFR tyrosine kinase inhibitor resistance 💬
 [2] FGFR2, FGFR3 💬 Infigratinib 💬 Infigratinib [1] 276 💬
91 EGFR tyrosine kinase inhibitor resistance 💬
 [5] FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib [5] 51, 85, 89, 227, 228 💬
92 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IGF1R 💬 Linsitinib 💬 Linsitinib [1] 232 💬
93 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IGF1R 💬 Mecasermin 💬 Mecasermin [6] 65, 78, 96, 168, 265, 299 💬
94 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IGF1R 💬 Teprotumumab 💬 Teprotumumab [1] 51 💬
95 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6 💬 Olokizumab 💬 Olokizumab [2] 46, 96 💬
96 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6 💬 Pirfenidone 💬 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
97 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6 💬 Pomalidomide 💬 Pomalidomide [5] 28, 51, 85, 227, 331 💬
98 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6 💬 Siltuximab 💬 Siltuximab [2] 28, 331 💬
99 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6 💬 Sirukumab 💬 Sirukumab [2] 41, 46 💬
100 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6R 💬 Sarilumab 💬 Sarilumab [5] 41, 46, 84, 107, 271 💬
101 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6R 💬 Satralizumab 💬 Satralizumab [3] 11, 13, 86 💬
102 EGFR tyrosine kinase inhibitor resistance 💬
 [1] IL6R 💬 Tocilizumab 💬 Tocilizumab [21]  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
103 EGFR tyrosine kinase inhibitor resistance 💬
 [1] JAK1 💬 Abrocitinib 💬 Abrocitinib [1] 84 💬
104 EGFR tyrosine kinase inhibitor resistance 💬
 [1] JAK1 💬 Filgotinib 💬 Filgotinib [6] 46, 53, 96, 97, 222, 271 💬
105 EGFR tyrosine kinase inhibitor resistance 💬
 [1] JAK1 💬 Itacitinib 💬 Itacitinib [4] 46, 51, 97, 228 💬
106 EGFR tyrosine kinase inhibitor resistance 💬
 [1] JAK1 💬 Upadacitinib 💬 Upadacitinib [8] 40, 41, 46, 49, 96, 97, 107, 271 💬
107 EGFR tyrosine kinase inhibitor resistance 💬
 [2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
108 EGFR tyrosine kinase inhibitor resistance 💬
 [2] JAK1, JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
109 EGFR tyrosine kinase inhibitor resistance 💬
 [2] JAK1, JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
110 EGFR tyrosine kinase inhibitor resistance 💬
 [2] JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
111 EGFR tyrosine kinase inhibitor resistance 💬
 [1] KDR 💬 Axitinib 💬 Axitinib [1] 34 💬
112 EGFR tyrosine kinase inhibitor resistance 💬
 [1] KDR 💬 Cediranib 💬 Cediranib [1] 34 💬
113 EGFR tyrosine kinase inhibitor resistance 💬
 [3] KDR, PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib [2] 28, 34 💬
114 EGFR tyrosine kinase inhibitor resistance 💬
 [2] MAP2K1, MAP2K2 💬 Binimetinib 💬 Binimetinib [1] 34 💬
115 EGFR tyrosine kinase inhibitor resistance 💬
 [2] MAP2K1, MAP2K2 💬 Cobimetinib 💬 Cobimetinib [1] 280 💬
116 EGFR tyrosine kinase inhibitor resistance 💬
 [2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [1] 34 💬
117 EGFR tyrosine kinase inhibitor resistance 💬
 [2] MAP2K1, MAP2K2 💬 Selumetinib 💬 Selumetinib [1] 34 💬
118 EGFR tyrosine kinase inhibitor resistance 💬
 [2] MAP2K1, MAP2K2 💬 Trametinib 💬 Trametinib [4]  2 , 34, 279, 280 💬
119 EGFR tyrosine kinase inhibitor resistance 💬
 [1] MTOR 💬 Everolimus 💬 Everolimus [9] 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
120 EGFR tyrosine kinase inhibitor resistance 💬
 [1] MTOR 💬 Sirolimus 💬 Sirolimus [40]  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
121 EGFR tyrosine kinase inhibitor resistance 💬
 [1] MTOR 💬 Temsirolimus 💬 Temsirolimus [1] 13 💬
122 EGFR tyrosine kinase inhibitor resistance 💬
 [1] PDGFRA 💬 Imatinib 💬 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
123 EGFR tyrosine kinase inhibitor resistance 💬
 [2] PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib [5]  6 ,  8 , 34, 51, 86 💬
124 EGFR tyrosine kinase inhibitor resistance 💬
 [2] PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib [2] 51, 85 💬
125 EGFR tyrosine kinase inhibitor resistance 💬
 [2] PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib [2] 51, 85 💬
126 EGFR tyrosine kinase inhibitor resistance 💬
 [1] PIK3CA 💬 Alpelisib 💬 Alpelisib [1] 138 💬
127 EGFR tyrosine kinase inhibitor resistance 💬
 [3] PIK3CA, PIK3CB, PIK3CD 💬 Leniolisib 💬 Leniolisib [2] 53, 65 💬
128 EGFR tyrosine kinase inhibitor resistance 💬
 [1] PIK3CD 💬 Parsaclisib 💬 Parsaclisib [3] 35, 53, 61 💬
129 EGFR tyrosine kinase inhibitor resistance 💬
 [1] PRKCB 💬 Enzastaurin 💬 Enzastaurin [1] 168 💬
130 EGFR tyrosine kinase inhibitor resistance 💬
 [1] SRC 💬 Bosutinib 💬 Bosutinib [2]  2 , 67 💬
131 EGFR tyrosine kinase inhibitor resistance 💬
 [1] SRC 💬 Saracatinib 💬 Saracatinib [3]  6 , 89, 272 💬
132 EGFR tyrosine kinase inhibitor resistance 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
133 EGFR tyrosine kinase inhibitor resistance 💬
 [1] VEGFA 💬 Bevacizumab 💬 Bevacizumab [6] 13, 34, 85, 87, 227, 280 💬
134 EGFR tyrosine kinase inhibitor resistance 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
135 Endocrine resistance 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
136 Endocrine resistance 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
137 Endocrine resistance 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
138 Endocrine resistance 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
139 Endocrine resistance 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
140 Endocrine resistance 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
141 Endocrine resistance 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
142 Endocytosis 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
143 Endocytosis 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
144 Endocytosis 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
145 Endocytosis 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
146 Endocytosis 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
147 Endocytosis 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
148 Endocytosis 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
149 Endometrial cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
150 Endometrial cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
151 Endometrial cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
152 Endometrial cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
153 Endometrial cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
154 Endometrial cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
155 Endometrial cancer 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
156 Epithelial cell signaling in Helicobacter pylori infection 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
157 Epithelial cell signaling in Helicobacter pylori infection 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
158 Epithelial cell signaling in Helicobacter pylori infection 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
159 Epithelial cell signaling in Helicobacter pylori infection 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
160 Epithelial cell signaling in Helicobacter pylori infection 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
161 Epithelial cell signaling in Helicobacter pylori infection 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
162 Epithelial cell signaling in Helicobacter pylori infection 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
163 ErbB signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
164 ErbB signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
165 ErbB signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
166 ErbB signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
167 ErbB signaling pathway 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
168 ErbB signaling pathway 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
169 ErbB signaling pathway 💬
 [3] EGFR, ERBB2, ERBB4 💬 Neratinib 💬 Neratinib [1] 34 💬
170 Estrogen signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
171 Estrogen signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
172 Estrogen signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
173 Estrogen signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
174 Estrogen signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
175 Estrogen signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
176 Estrogen signaling pathway 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
177 Focal adhesion 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
178 Focal adhesion 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
179 Focal adhesion 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
180 Focal adhesion 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
181 Focal adhesion 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
182 Focal adhesion 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
183 Focal adhesion 💬
 [4] EGFR, ERBB2, FLT4, KDR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
184 FoxO signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
185 FoxO signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
186 FoxO signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
187 FoxO signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
188 FoxO signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
189 FoxO signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
190 FoxO signaling pathway 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
191 Gap junction 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
192 Gap junction 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
193 Gap junction 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
194 Gap junction 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
195 Gap junction 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
196 Gap junction 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
197 Gap junction 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
198 Gastric cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
199 Gastric cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
200 Gastric cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
201 Gastric cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
202 Gastric cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
203 Gastric cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
204 Gastric cancer 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
205 Glioma 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
206 Glioma 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
207 Glioma 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
208 Glioma 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
209 Glioma 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
210 Glioma 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
211 Glioma 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
212 GnRH signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
213 GnRH signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
214 GnRH signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
215 GnRH signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
216 GnRH signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
217 GnRH signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
218 GnRH signaling pathway 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
219 Hepatitis C 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
220 Hepatitis C 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
221 Hepatitis C 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
222 Hepatitis C 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
223 Hepatitis C 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
224 Hepatitis C 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
225 Hepatitis C 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
226 Hepatocellular carcinoma 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
227 Hepatocellular carcinoma 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
228 Hepatocellular carcinoma 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
229 Hepatocellular carcinoma 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
230 Hepatocellular carcinoma 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
231 Hepatocellular carcinoma 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
232 Hepatocellular carcinoma 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
233 HIF-1 signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
234 HIF-1 signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
235 HIF-1 signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
236 HIF-1 signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
237 HIF-1 signaling pathway 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
238 HIF-1 signaling pathway 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
239 HIF-1 signaling pathway 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
240 Human cytomegalovirus infection 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
241 Human cytomegalovirus infection 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
242 Human cytomegalovirus infection 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
243 Human cytomegalovirus infection 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
244 Human cytomegalovirus infection 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
245 Human cytomegalovirus infection 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
246 Human cytomegalovirus infection 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
247 Human papillomavirus infection 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
248 Human papillomavirus infection 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
249 Human papillomavirus infection 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
250 Human papillomavirus infection 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
251 Human papillomavirus infection 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
252 Human papillomavirus infection 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
253 Human papillomavirus infection 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
254 JAK-STAT signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
255 JAK-STAT signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
256 JAK-STAT signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
257 JAK-STAT signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
258 JAK-STAT signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
259 JAK-STAT signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
260 JAK-STAT signaling pathway 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
261 MAPK signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
262 MAPK signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
263 MAPK signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
264 MAPK signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
265 MAPK signaling pathway 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
266 MAPK signaling pathway 💬
 [3] EGFR, ERBB2, ERBB4 💬 Neratinib 💬 Neratinib [1] 34 💬
267 MAPK signaling pathway 💬
 [4] EGFR, ERBB2, FLT4, KDR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
268 Melanoma 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
269 Melanoma 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
270 Melanoma 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
271 Melanoma 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
272 Melanoma 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
273 Melanoma 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
274 Melanoma 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
275 MicroRNAs in cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
276 MicroRNAs in cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
277 MicroRNAs in cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
278 MicroRNAs in cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
279 MicroRNAs in cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
280 MicroRNAs in cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
281 MicroRNAs in cancer 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
282 Non-small cell lung cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
283 Non-small cell lung cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
284 Non-small cell lung cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
285 Non-small cell lung cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
286 Non-small cell lung cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
287 Non-small cell lung cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
288 Non-small cell lung cancer 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
289 Oxytocin signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
290 Oxytocin signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
291 Oxytocin signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
292 Oxytocin signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
293 Oxytocin signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
294 Oxytocin signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
295 Oxytocin signaling pathway 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
296 Pancreatic cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
297 Pancreatic cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
298 Pancreatic cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
299 Pancreatic cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
300 Pancreatic cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
301 Pancreatic cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
302 Pancreatic cancer 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
303 Parathyroid hormone synthesis, secretion and action 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
304 Parathyroid hormone synthesis, secretion and action 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
305 Parathyroid hormone synthesis, secretion and action 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
306 Parathyroid hormone synthesis, secretion and action 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
307 Parathyroid hormone synthesis, secretion and action 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
308 Parathyroid hormone synthesis, secretion and action 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
309 Parathyroid hormone synthesis, secretion and action 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
310 Pathways in cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
311 Pathways in cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
312 Pathways in cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
313 Pathways in cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
314 Pathways in cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
315 Pathways in cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
316 Pathways in cancer 💬
 [3] EGFR, ERBB2, FLT4 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
317 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
318 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
319 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
320 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
321 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
322 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
323 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
324 Phospholipase D signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
325 Phospholipase D signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
326 Phospholipase D signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
327 Phospholipase D signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
328 Phospholipase D signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
329 Phospholipase D signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
330 Phospholipase D signaling pathway 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
331 PI3K-Akt signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
332 PI3K-Akt signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
333 PI3K-Akt signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
334 PI3K-Akt signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
335 PI3K-Akt signaling pathway 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
336 PI3K-Akt signaling pathway 💬
 [3] EGFR, ERBB2, ERBB4 💬 Neratinib 💬 Neratinib [1] 34 💬
337 PI3K-Akt signaling pathway 💬
 [4] EGFR, ERBB2, FLT4, KDR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
338 Prostate cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
339 Prostate cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
340 Prostate cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
341 Prostate cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
342 Prostate cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
343 Prostate cancer 💬
 [2] EGFR, ERBB2 💬 Neratinib 💬 Neratinib [1] 34 💬
344 Prostate cancer 💬
 [2] EGFR, ERBB2 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
345 Proteoglycans in cancer 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
346 Proteoglycans in cancer 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
347 Proteoglycans in cancer 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
348 Proteoglycans in cancer 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
349 Proteoglycans in cancer 💬
 [2] EGFR, ERBB2 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
350 Proteoglycans in cancer 💬
 [3] EGFR, ERBB2, ERBB4 💬 Neratinib 💬 Neratinib [1] 34 💬
351 Proteoglycans in cancer 💬
 [3] EGFR, ERBB2, KDR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
352 Rap1 signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
353 Rap1 signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
354 Rap1 signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
355 Rap1 signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
356 Rap1 signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
357 Rap1 signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
358 Rap1 signaling pathway 💬
 [3] EGFR, FLT4, KDR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
359 Ras signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
360 Ras signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
361 Ras signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
362 Ras signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
363 Ras signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
364 Ras signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
365 Ras signaling pathway 💬
 [3] EGFR, FLT4, KDR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
366 Regulation of actin cytoskeleton 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
367 Regulation of actin cytoskeleton 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
368 Regulation of actin cytoskeleton 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
369 Regulation of actin cytoskeleton 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
370 Regulation of actin cytoskeleton 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
371 Regulation of actin cytoskeleton 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
372 Regulation of actin cytoskeleton 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
373 Relaxin signaling pathway 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
374 Relaxin signaling pathway 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
375 Relaxin signaling pathway 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
376 Relaxin signaling pathway 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
377 Relaxin signaling pathway 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
378 Relaxin signaling pathway 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
379 Relaxin signaling pathway 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬
380 Shigellosis 💬
 [1] EGFR 💬 Cetuximab 💬 Cetuximab [2] 51, 86 💬
381 Shigellosis 💬
 [1] EGFR 💬 Erlotinib 💬 Erlotinib [1] 94 💬
382 Shigellosis 💬
 [1] EGFR 💬 Gefitinib 💬 Gefitinib [1] 75 💬
383 Shigellosis 💬
 [1] EGFR 💬 Icotinib 💬 Icotinib [1] 34 💬
384 Shigellosis 💬
 [1] EGFR 💬 Lapatinib 💬 Lapatinib [3] 34, 74, 75 💬
385 Shigellosis 💬
 [1] EGFR 💬 Neratinib 💬 Neratinib [1] 34 💬
386 Shigellosis 💬
 [1] EGFR 💬 Tesevatinib 💬 Tesevatinib [1] 67 💬

Back to top